Amicus Therapeutics announced topline results from the Phase III PROPEL pivotal trial of AT-GAA (cipaglucosidase alfa and miglustat) for late-onset Pompe disease.
https://www.pharmalive.com/wp-content/uploads/2021/02/Amicus-Puts-Positive-Spin-on-Failure-of-its-Phase-III-Trial-for-Pompe-Disease-BioSpace-2-12-21.jpeg350625Andrew Humphreyshttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngAndrew Humphreys2021-02-12 12:19:182021-02-12 15:32:28Phase III Trial Failure for Pompe Disease Drug